Ken Griffin Humacyte, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.11 - $9.46 $202,356 - $374,616	39,600 Added 319.35%	52,000 $282,000
Q2 2024 Aug 14, 2024	SELL	$2.87 - $9.1 $9,184 - $29,120	-3,200 Reduced 20.51%	12,400 $59,000
Q1 2024 May 15, 2024	BUY	$2.57 - $4.84 $36,237 - $68,244	14,100 Added 940.0%	15,600 $48,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $4.48 $1,925 - $3,136	700 Added 87.5%	1,500 $4,000
Q2 2023 Aug 14, 2023	BUY	$2.86 - $4.97 $2,288 - $3,976	800 New	800 $2,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.62 $21,816 - $39,096	-10,800 Reduced 45.96%	12,700 $26,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $5.14 $10,370 - $43,690	8,500 Added 56.67%	23,500 $77,000

150

35.1M

279K

607K

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $458M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.